Phase II proof of concept trial of MDGN 201 (sustained erythropoietin therapy using the Biopump technology platform) in patients with beta thalassaemia intermedia.

Trial Profile

Phase II proof of concept trial of MDGN 201 (sustained erythropoietin therapy using the Biopump technology platform) in patients with beta thalassaemia intermedia.

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2014

At a glance

  • Drugs MDGN 201 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2014 New trial record
    • 15 Oct 2014 Initial results are expected in the second half of 2015, according to a Medgenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top